Our executive team has over 60 years of combined industry experience, and a proven track record of leadership, global registration, and lifecycle management for over 20 products.
Mr. Wise joined Achaogen as Chief Operating Officer in 2015 and, in February 2017 he was appointed President and Chief Operating Officer. Prior to Achaogen, Mr. Wise spent 13 years at Genentech, where he most recently established and led the Cross BioOncology franchise as Vice President, Cross BioOncology. In this role, Mr. Wise spearheaded cross-portfolio oncology initiatives, including key account management, marketing, managed markets, companion diagnostics, pipeline commercialization, and long-term oncology strategy. During his time at Genentech, Mr. Wise also held several other leadership positions of increasing responsibility, including Senior Director, Franchise Head and Life Cycle Leader of the Lytics franchise, with overall commercial responsibility for Genentech’s hospital-based Lytics business. He previously served as a Sales Director in BioOncology, Marketing Director in Cystic Fibrosis and Immunology, and Interactive Marketing Director where he built Genentech’s digital marketing capabilities. Prior to joining Genentech in 2002, Mr. Wise worked in consumer marketing, e-commerce and online marketing outside of the healthcare industry in leadership positions at Gap, Inc. and Webvan. Mr. Wise received a Bachelor of Arts degree in Business Economics from University of California, Santa Barbara, and a Masters of Business Administration degree from University of California, Berkeley, Haas School of Business.
Ms. Dorling joined Achaogen as Chief Commercial Officer in 2017. Prior to Achaogen, Ms. Dorling spent 14 years at Genentech and Roche where, as Vice President of Global Product Strategy, Breast Cancer at Roche/Genentech, she was responsible for developing and implementing global commercialization and lifecycle strategies for the Breast Cancer Franchise. Previously, as Vice President of the Lytics Franchise, Ms. Dorling lead hospital-focused Sales and Marketing teams that promoted Activase and Cathflo in the acute care setting. Ms. Dorling also had multiple roles with increasing responsibility in Market Analysis and Strategy in Ophthalmology, Oncology, and ultimately leading multiple functions with portfolio-wide responsibility. Prior to joining Genentech Ms. Dorling had several roles in Business Development at Altus Biologics, DNA Sciences, and Clontech Laboratories. Ms. Dorling has a Bachelor of Arts in Molecular and Cellular Biology from the University of California at Berkeley, a Master's in Science in Pharmacology and Cancer Biology from Duke University, and a Master's in Business Administration from the Haas School of Business at the University of California at Berkeley.
Ms. Sarpangal joined Achaogen in 2009 and is our Senior Vice President of Corporate and People Strategy. She has previously served as Achaogen’s Vice President of Human Resources and Corporate Affairs and, prior to that, as Sr. Director of Finance & Operations and Director of Strategic Marketing. Ms. Sarpangal has prior experience as the Vice President of Finance & Operations at Identified, an HR data analytics company, an engagement manager at McKinsey & Company, a global management consulting firm, and a healthcare investment banking analyst at Goldman, Sachs & Co. She received a Bachelors of Arts in Economics and Molecular & Cell Biology from University of California, Berkeley, and a Masters of Business Administration from the Stanford Graduate School of Business.
Dr. Swem was appointed Chief Scientific Officer in February 2017 and, prior to that, was the Vice President, Head of Research at Achaogen since 2015. Prior to this position, Dr. Swem spent just under two years as the Director of Achaogen’s Therapeutic Antibody Program, where he developed a state-of-the-art antibody discovery platform to rapidly identify rare functional antibodies to treat serious human infectious diseases. Before joining Achaogen, Dr. Swem spent approximately four years as a Scientist in the Department of Infectious Disease at Genentech. During his tenure at Genentech, he developed the anti-influenza A program, the anti-influenza B program, and began a small molecule anti-bacterial program. Under his leadership, the anti-influenza teams established an innovative human B cell enrichment and cloning technique to discover rare functional antibodies. This work led to the discovery of two broadly neutralizing antibodies targeting influenza A and influenza B.Dr. Swem served as the research lead on the anti-influenza development teams, which successfully transitioned the anti-influenza A antibody through Phase 1 and Phase 2 clinical trials and the anti-influenza B antibody into early development. The combination of these two human antibodies could constitute a therapy to treat all serious influenza infections. Prior to working at Genentech, Dr. Swem completed his postdoctoral work with Dr. Bonnie Bassler at Princeton University, where he successfully carried out multiple high-throughput screens to identify small molecule inhibitors of bacterial virulence cascades. Dr. Swem received his Ph.D. in microbiology from Indiana University.